Theratechnologies Inc T.TH

Q&A indicates LSA has brought some good new investors

[SPCEO1]

Very scientific questions indicate to me that US based institutions are indeed on this call - a very good sign for LSA's capabilities.

[Wino115]

Or JFM Scarlet  and QWERTY stuffed the Q&A box.    

[qwerty22]

I'm fore-seeing an "A" on the weekly report card, that was great. Very professional.

[Wino115]

Jam-packed with good solid and well-explained and diagramed information. In the past, we've all commented how their data and articulation just wasn't enough to convince potential investors to take a look. Obviously POC hard data will really get people to look, but I have to say this should get a few intrigued with the possibility.  It won't be huge, but they were very logical how

[SPCEO1]

I am a tough grader and don't grade on a curve, but it is clear to me that this was a presentation that will play well with US institutions. LSA clearly was beneficial in helping them put that together. It was a top notch presentation deserving of a high grade. All three presnters were excellenet.  Let's see how the follow through goes.

[qwerty22]

I got two Qs asked

[Wino115]

I think we snuffed out your's and JFMs questions -- the 2nd MOA one and the imaging one. Mine didn't get asked as it was to crass I guess -- what do you think is the commercial opportunity for this platform?  and , do you think clinics will use it at the 2L and 3L level if sortilin is expressed enough?

[qwerty22]

That was one thing missing any talk about commercial, comparable companies, ADC market etc

[SPCEO1]

Like Wino, I asked a commercially oriented question that was ignored. I suspect LSA wanted to keep this one focused on science.

[qwerty22]

There are some many targets on cancer cells and so many drugs going after those targets it's interesting to hear them really try to differentiate this program based on the specialness of SORT as a "scavenger". There was one question about who else is studying SORT and why nobody else is really going after it. I think that it's reasonable to wonder whether SORT is a "marginal

[jfm1330]

Beliveau subtly looked and sounded like the cat that ate the canary... He is the guy at the basis of all that. The key here is the nature of the sortilin receptor as a scavenger receptor that expresses itself more and more as a cancer evolves into a more agressive stage. Other than that, We now know why they take all comers, it confirms what I thought, but we now know that they take biopsies along

[SPCEO1]

Paul touched on many of the things you have spoken about in the slide belwo and they clearly are not lacking in imaginination about the possibilities. But is this something a small company like TH can handle on their own? Beliveau and Marsolais seem impressive to us but given the size of this thing, should they be quick to partner at least some aspects of this opportunity versus holding things

[jfm1330]

I am very surprised to read that, especially coming from you. You lost it totally over the last financing, because in your view they gave away value you partly owned, and now you would be open to give away even more value to an opportunistic partner? My view on this is that the are competent, they know what they do, and the day they will come out with very positive hard data on humans, the SP wil

[SPCEO1]

You are surprise to read me asking a logical question???? But thanks for giving me a good answer to it.

[qwerty22]

It's not necessary to execute on all these things now. There were hints that on the things they do need to get moving on they are already doing that. If the data is good then the program will grow over time and the company can expand their capabilities alongside. There's no need to judge whether today's little THTX can handle all this. 

[jeffm34]

Disagree entirely with that assessment. There is no way TH can explore and capitalize on all the opportunities of this program by themselves.  It is massive. They need trials to explore effects on different cancers, different payloads, different dosing regimens.  Do you want 100% of a small pie or 50% of something that is multiple times larger. 

[qwerty22]

I take half that list to be aspirational and half to be of practical necessity. And what I heard today was that on the practical necessity front they are already executing. What I want is proof of concept going all the way to approval in one indication, the way almost every NME goes (except if your CYDY). I'm happy for a partner but they'll do exactly that as well. They won't do

[jfm1330]

THe stock price is not moving much after such a great presentation. We will see if there is a delayed reaction in the coming days, but if not, it will kill all the debate over bad promotion or it will prove that most investor are not understanding much of the science they tried to explained today in the simplest possible way. One thing I forgot that was very positive from the presentation, is the

[SPCEO1]

In addition to the probability that we may be far enough into the dose escalation trial to know that no weird safety signals have gone off and that TH may already have an equivalent dose of the normal dose of Docetaxel safely in humans, I would say the vibe given off by these presenters, who all know much more than they told us, was very positive.  The delay in getting the results of the

[qwerty22]

This is the timing I've always understood. Late summer for part one (28weeks). And part 2 getting going and rolling into 2022. Based on what other companies do I don't think they necessarily wait until summer 2022 for first data in part2, there can be interim data readouts if they see benefit in that. It might be possible to put interim data out at the turn of the year. Plus if there are

[Wino115]

If we see it work, that will likely be the way to stay independent and maximize the value.  If a big pharma buys, they are less likely to license it out to serious competitors in similar spaces.  THTX may not have that issue and can license it to both big pharma competitors using, say, their latest TKIs or Immunolncology drugs.   It's almost more valuable as an independent with

[qwerty22]

lol having endlessly argued that all-comers was a mistake, now he's fine with it, in fact it confirms what he always thought. And he invents aspects of the protocol to fit that. MTD is not just being determined by patients over-expressing Sortilin, nobody said that and it's not part of the protocol. It's being determined by all-comers, that's why they are recruiting all-comers

[palinc2000]

Talking on both sides of his mouth is his trademark!!! He is so full of himself!!! Cant barely read thru his posts .... 

[qwerty22]

I asked about VM and whether we are talking about a second MOA. And 2nd question was if Melanoma would get incorporated into the trial. I liked it all but what I really liked was the last slide in Paul's summing up because it tells me at least from the clinical perspective they are thinking about all the various aspects of what this program is going to need going into the future. Also

[scarlet1967]

I got few answered a lot of information no direct update on human trial but it is progressing so far well, tried to take notes but it was packed with data.